Sam Lynch, DMD, DMSc, CEO and Chairman, has nearly 30 years of successful experience in leading private and public biomedical companies, M&A, and regenerative medicine product development. He is a graduate and former faculty member of Harvard Medical School and Harvard Dental School. He founded and was CEO of BMTI over a 12 year period from product concept through multiple FDA approved combination products for healing of musculoskeletal tissues. Investors exited via an IPO, public equity sales and a trade sale valued at $400 million.